2.
各组患者的基因型和伊马替尼谷浓度水平
Genotyping results and trough levels of imatinib in the two groups
| SNPs | Genotype | Total | Study group (n=50) | Control group (n=50) | χ2/t | P |
| CYP3A5-A6986G(rs776746) | ||||||
| AA | 13 (13.00%) | 8 (57.14%) | 6 (42.86%) | |||
| AG | 41 (41.00%) | 22 (55.00%) | 18 (45.00%) | 1.468 | 0.480 | |
| GG | 46 (46.00%) | 20 (43.48%) | 26 (56.52%) | |||
| MDR1-C1236T (rs1128503) | ||||||
| CC | 13 (13.00%) | 10(76.92%) | 3 (23.08%) | |||
| CT | 65 (65.00%) | 33 (50.00%) | 33 (50.00%) | 6.103 | 0.047 | |
| TT | 22 (22.00%) | 7 (33.33%) | 14(66.67%) | |||
| MDR1-C3435T (rs1045642) | ||||||
| CC | 14(14.00%) | 11 (73.33%) | 4 (26.67%) | |||
| CT | 48 (48.00%) | 26 (56.52%) | 20 (43.48%) | 8.383 | 0.015 | |
| TT | 38 (38.00%) | 13 (33.33%) | 26 (66.67%) | |||
| MDR1-G2677T/A (rs2032582) | ||||||
| GG | 10(10.00%) | 7 (70.00%) | 3 (30.00%) | |||
| TA | 7 (7.00%) | 4 (57.14%) | 3 (42.86%) | |||
| GA | 3 (3.00%) | 2 (66.67%) | 1 (33.33%) | 3.856 | 0.426 | |
| GG | 42 (42.00%) | 22 (52.38%) | 20 (47.62%) | |||
| TA | 38 (38.00%) | 15 (39.47%) | 23 (60.52%) | |||
| Trough levels of imatinib (ng/mL) | ||||||
| 1564.31±851.65 | 2173.55±765.44 | 3.762 | 0.000 | |||